ADC Therapeutics SA: Form 6-K Summary
Business context and reporting period
ADC Therapeutics SA filed a Form 6-K in May 2021. The filing identifies unaudited IFRS condensed consolidated interim financial statements for the three months ended March 31, 2021 as Exhibit 99.1, but the provided filing text contains only the cover page and exhibit index.
Financial results and liquidity
The provided text does not include clear values for revenue, net income or loss, cash flow, margins, debt, liquidity, cash balances, or other financial metrics.
Changes versus the prior comparable period
The filing text provided does not include comparative-period financial results or a discussion of material changes.
Guidance, outlook, risks, and unusual items
The filing text does not provide guidance, outlook commentary, risk disclosures, contingencies, or information on unusual items. It references a Management’s Discussion and Analysis in Exhibit 99.2 and a press release in Exhibit 99.3, but their contents are not included.
Important facts to verify
- Review Exhibit 99.1 for the March 31, 2021 interim financial statements and comparative figures.
- Review Exhibit 99.2 for operating trends, liquidity analysis, commitments, risks, and management commentary.
- Review Exhibit 99.3 for reported results, pipeline updates, and any guidance or outlook.
- Confirm the impact of the amended Articles of Association identified as Exhibit 99.4.
- Note that the filing was signed by Jennifer Creel, Chief Financial Officer, on May 6, 2021.